TriangleNCT02362035 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 104 weeks
What was measured
The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause
Analysis population: All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the the combination study treatment.
Groups in this outcome
Acalabrutinib + Pembrolizumab
All participants in this study received both study drugs and were therefore analysed together as a single treatment arm. Participants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment. The study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.
| Group | Source count |
|---|---|
| Acalabrutinib + Pembrolizumab | 161 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Acalabrutinib + Pembrolizumab | 28.5 | Not reported | 9.0 | 36.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9.0
- upper Limit
- 36.4
- value
- 28.5
- denoms
- counts
- group Id
- OG000
- value
- 161
- units
- Participants
- description
- The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All participants in this study received both study drugs and were therefore analysed together as a single treatment arm. Participants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment. The study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.
- id
- OG000
- title
- Acalabrutinib + Pembrolizumab
- param Type
- MEDIAN
- population Description
- All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the the combination study treatment.
- reporting Status
- POSTED
- time Frame
- 104 weeks
- title
- Duration of Response
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice